Geron Corporation (NASDAQ: GERN) stock rose 84% in March, according to data provided by S&P Global Market Intelligence .
Shares saw significant upward momentum following the company's fourth-quarter earnings release and indications that its blood cancer drug, imetelstat, is producing encouraging trial results. Geron Corporation has a market cap of roughly $600 million, and its valuation is largely dependent on the development and marketing of imetelstat, so shares tend to see big pricing swings in relation to the compound's outlook.
Image source: Getty Images.
Geron Corporation published fourth-quarter and full-year earnings results on March 16 and held a conference call in which management made comments indicating that trials for imetelstat were yielding favorable results. Imetelstat is an experimental drug and Geron's key product, and the company's shares skyrocketed following management's promising comments.
Geron is partnered with Johnson & Johnson (NYSE: JNJ) for the development of imetelstat and is waiting for a decision from the healthcare giant about whether additional testing and development will take place. If J&J opts to pursue development of the drug, Geron will receive a $135 million payment from the company and have the opportunity to receive additional, milestone-based payments.
Johnson & Johnson is due to report earnings on April 17 and is expected to give an update on its clinical trial pipeline on that date. The company has listed imetelstat among its list of potential blockbuster drugs for two years running, and Geron shares will likely see big movement depending on whether its partner once again presents a favorable outlook for the drug.
More From The Motley Fool
- 3 Growth Stocks at Deep-Value Prices
- 5 Expected Social Security Changes in 2018
- 6 Years Later, 6 Charts That Show How Far Apple, Inc. Has Come Since Steve Jobs' Passing
- 10 Best Stocks to Buy Today
- The $16,122 Social Security Bonus You Cannot Afford to Miss
- Bitcoin's Biggest Competitor Isn't Ethereum -- It's This
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has the following options: short May 2018 $140 calls on Johnson & Johnson. The Motley Fool has a disclosure policy.